BTI
XENE icon

Blue Trust Inc’s Xenon Pharmaceuticals XENE Stock Holding History

Blue Trust Inc’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7K Sell
724
-21
-3% -$1.17K ﹤0.01% 1397
2026
Q1 		$43.3K Hold
745
– – ﹤0.01% 1388
2025
Q4 		$33.4K Buy
745
+717
+2,561% +$30.1K ﹤0.01% 1498
2025
Q3 		$1.12K Hold
28
– – ﹤0.01% 2295
2025
Q2 		$876 Sell
28
-242
-90% -$7.89K ﹤0.01% 2266
2025
Q1 		$9.06K Buy
270
+22
+9% +$835 ﹤0.01% 1930
2024
Q4 		$9.72K Sell
248
-760
-75% -$31.4K ﹤0.01% 1930
2024
Q3 		$39.3K Buy
1,008
+641
+175% +$25.8K ﹤0.01% 1667
2024
Q2 		$15.8K Buy
367
+340
+1,259% +$13.6K ﹤0.01% 1765
2024
Q1 		$1.16K Sell
27
-95
-78% -$4.37K ﹤0.01% 1915
2023
Q4 		$4K Buy
+122
New +$4.31K ﹤0.01% 1962
2023
Q1 		– Sell
-29
Closed -$1K – 2667
2022
Q4 		$1K Buy
+29
New +$1.06K ﹤0.01% 2161

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Blue Trust Inc's XENE Position: Q2 2026 in Review

Blue Trust Inc reduced its Xenon Pharmaceuticals (XENE) stake by 2.8% in Q2 2026, selling an estimated $1.17K and leaving 724 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Blue Trust Inc first reported a position in XENE in Q4 2022 and has held it in 12 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Blue Trust Inc held 724 shares of Xenon Pharmaceuticals worth $43.7K as of Q2 2026.
  • Blue Trust Inc sold 21 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.17K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1397 holding.
  • Blue Trust Inc first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.